PDI 320

Drug Profile

PDI 320

Alternative Names: PDI-320

Latest Information Update: 19 Feb 2016

Price : $50

At a glance

  • Originator PreCision Dermatology
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Rosacea

Most Recent Events

  • 08 Jul 2014 PreCision Dermatology has been acquired by Valeant Pharmaceuticals International
  • 17 Jun 2013 Phase-II clinical trials in Rosacea in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top